Effect of extended dosing interval of anti-TNF-alpha NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis.

Tsutomu TakeuchiMegumi NakanishiMasafumi KawanishiHironori YamasakiYoshiya Tanaka

Published in: Modern rheumatology (2023)

In patients with RA and maintained DAS28-ESR <3.2 with ozoralizumab, efficacy was sustained and well tolerated after the dosing interval was extended from Q4W to Q8W.

Keyphrases

disease activity
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
systemic lupus erythematosus
juvenile idiopathic arthritis
interstitial lung disease
systemic sclerosis